Market capitalization | $310.81m |
Enterprise Value | $294.88m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 139.75 |
EV/Sales (TTM) EV/Sales | 8.50 |
P/S ratio (TTM) P/S ratio | 8.96 |
P/B ratio (TTM) P/B ratio | 19.45 |
Revenue growth (TTM) Revenue growth | 5.64% |
Revenue (TTM) Revenue | $34.68m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
2 Analysts have issued a Eton Pharmaceuticals, Inc. forecast:
2 Analysts have issued a Eton Pharmaceuticals, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 35 35 |
6%
6%
|
|
Gross Profit | 21 21 |
14%
14%
|
|
EBITDA | -4.13 -4.13 |
251%
251%
|
EBIT (Operating Income) EBIT | -5.22 -5.22 |
380%
380%
|
Net Profit | -5.48 -5.48 |
346%
346%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Eton Pharmaceuticals, Inc. engages in the development and commercialization of prescription drug products. It focuses on product candidates that are liquid in formulation, including injectables, oral liquids and ophthalmics. The company was founded in April 2017 and is headquartered in Deer Park, IL.
Head office | United States |
CEO | Sean Brynjelsen |
Employees | 30 |
Founded | 2017 |
Website | www.etonpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.